These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21182150)

  • 41. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States.
    Strom BL
    Ann Ist Super Sanita; 1991; 27(2):235-7. PubMed ID: 1755576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Certification of Electronic Health Record systems and the importance of the validation of clinical archetypes.
    De Moor G; Kalra D; Devlies J
    Stud Health Technol Inform; 2008; 141():82-91. PubMed ID: 18953128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
    Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug-induced cancer.
    Prescrire Int; 2010 Feb; 19(105):21. PubMed ID: 20455337
    [No Abstract]   [Full Text] [Related]  

  • 46. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 47. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study.
    Meijer WM; Cornel MC; Dolk H; de Walle HE; Armstrong NC; de Jong-van den Berg LT;
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):675-82. PubMed ID: 16761260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Informed consent and phase IV non-interventional drug research.
    Bernabe RD; van Thiel GJ; van Delden JJ; Raaijmakers JA
    Curr Med Res Opin; 2011 Mar; 27(3):513-8. PubMed ID: 21208152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Healthcare databases in Europe for studying medicine use and safety during pregnancy.
    Charlton RA; Neville AJ; Jordan S; Pierini A; Damase-Michel C; Klungsøyr K; Andersen AM; Hansen AV; Gini R; Bos JH; Puccini A; Hurault-Delarue C; Brooks CJ; de Jong-van den Berg LT; de Vries CS
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):586-94. PubMed ID: 24664855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minimal standard terminology for digestive endoscopy: results of prospective testing and validation in the GASTER project.
    Delvaux M; Crespi M; Armengol-Miro JR; Hagenmüller F; Teuffel W; Spencer KB; Stettin J; Zwiebel FM
    Endoscopy; 2000 Apr; 32(4):345-55. PubMed ID: 10774976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Automatic generation of MedDRA terms groupings using an ontology.
    Declerck G; Bousquet C; Jaulent MC
    Stud Health Technol Inform; 2012; 180():73-7. PubMed ID: 22874155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Research on drug safety and effectiveness using pharmacoepidemiological databases.
    Andersen M
    J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741
    [No Abstract]   [Full Text] [Related]  

  • 55. Methods for observational post-licensure medical product safety surveillance.
    Nelson JC; Cook AJ; Yu O; Zhao S; Jackson LA; Psaty BM
    Stat Methods Med Res; 2015 Apr; 24(2):177-93. PubMed ID: 22138688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A MiniReview of the use of hospital-based databases in observational inpatient studies of drugs.
    Larsen MD; Cars T; Hallas J
    Basic Clin Pharmacol Toxicol; 2013 Jan; 112(1):13-8. PubMed ID: 22901097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Description of a drug hierarchy in a concept-based reference terminology.
    Kim JM; Frosdick P
    Proc AMIA Symp; 2001; ():314-8. PubMed ID: 11825202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A portable communicative architecture for electronic healthcare records: the Good European Healthcare Record project (Aim project A2014).
    Griffith SM; Kalra D; Lloyd DS; Ingram D
    Medinfo; 1995; 8 Pt 1():223-6. PubMed ID: 8591158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Is it possible to do pharmaco-epidemiological research using electronic databanks in the Swiss health care system?].
    Meier ChR
    Praxis (Bern 1994); 2003 May; 92(21):997-1000. PubMed ID: 12806695
    [No Abstract]   [Full Text] [Related]  

  • 60. [Observational cohort studies. Overview and some examples from the field of drug safety].
    Holmqvist M; Raaschou P; Neovius M; Askling J
    Lakartidningen; 2013 Jan 16-22; 110(3):82-4. PubMed ID: 23424984
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.